期刊
CANCERS
卷 14, 期 15, 页码 -出版社
MDPI
DOI: 10.3390/cancers14153754
关键词
gene expression; clear-cell renal cell carcinoma; disease progression; prognostic factors; biomarkers; RNA sequencing
类别
资金
- Hospital Clinic de Barcelona
In this study, molecular markers for disease progression in ccRCC were identified and a gene expression-based signature was developed. This signature enhances the prediction of prognosis and could be used for personalized disease management.
Simple Summary In this study, we identified molecular markers for disease progression from ccRCC tissue samples. Using the selected biomarkers and clinical data from the TCGA cohort, we developed a gene expression-based signature which enhances the prognostic prediction of clinicopathological variables and could help to provide personalized disease management. The inaccuracy of the current prognostic algorithms and the potential changes in the therapeutic management of localized ccRCC demands the development of an improved prognostic model for these patients. To this end, we analyzed whole-transcriptome profiling of 26 tissue samples from progressive and non-progressive ccRCCs using Illumina Hi-seq 4000. Differentially expressed genes (DEG) were intersected with the RNA-sequencing data from the TCGA. The overlapping genes were used for further analysis. A total of 132 genes were found to be prognosis-related genes. LASSO regression enabled the development of the best prognostic six-gene panel. Cox regression analyses were performed to identify independent clinical prognostic parameters to construct a combined nomogram which includes the expression of CERCAM, MIA2, HS6ST2, ONECUT2, SOX12, TMEM132A, pT stage, tumor size and ISUP grade. A risk score generated using this model effectively stratified patients at higher risk of disease progression (HR 10.79; p < 0.001) and cancer-specific death (HR 19.27; p < 0.001). It correlated with the clinicopathological variables, enabling us to discriminate a subset of patients at higher risk of progression within the Stage, Size, Grade and Necrosis score (SSIGN) risk groups, pT and ISUP grade. In summary, a gene expression-based prognostic signature was successfully developed providing a more precise assessment of the individual risk of progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据